



## Clinical Status 2004

### Clinical Status 2004



20. Dezember 2004

**Australian Cancer Technology Ltd.** (ASX:ACU), Perth, Australia  
**Bioaccelerate Inc.**, New York, N.Y.  
**RESprotect GmbH**, Dresden, Germany

- \* Product: RP101
  - \* Business: Cancer
  - \* Molecular target: NA
  - \* Description: Inhibits induced chemoresistance and enhances chemosensitivity
  - \* Indication: Treat metastatic pancreatic cancer
  - \* Endpoint: NA
  - \* Status: Started Phase II
  - \* Milestone: NA
- \* The partners began an 8-month, double-blind, placebo-controlled, German Phase II trial in 22 patients with metastatic pancreatic cancer. The patients will receive RP101 tablets in combination with gemcitabine.

[download original PDF document](#)